

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Diagnostics Assessment Programme

Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test)

### Stakeholder list

#### **Manufacturer(s)**

Abbott (Diagnostics Division)  
BioMerieux  
BioPorto Diagnostics A/S  
Ortho Clinical Diagnostics

#### **Professional groups**

British Renal Society  
Faculty of Intensive Care Medicine  
Institute of Biomedical Sciences  
Renal Association  
Royal College of Physicians

#### **Patient/carer groups**

Vasculitis UK

#### **External Assessment Group**

Aberdeen Health Technology Assessment Group

#### **Others**

Department of Health  
Healthcare Improvement Scotland  
Medicines and Healthcare products Regulatory Agency  
NHS England  
Welsh Government

## **Definitions:**

### Stakeholders

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, manufacturers of the technology, national organisations that represent healthcare professions who operate or use the results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.

### External Assessment Group (EAG)

An independent academic group commissioned by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) that prepares a systematic review of the clinical and cost effectiveness of the technology(ies).